EU Panel Backs Olaparib for BRCA-Mutant Advanced Breast Cancer

March 1, 2019 – The European Medicine Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to olaparib tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer. If approved, olaparib would be indicated for those who were previously been treated with an anthracycline and a taxane in the neoadjuvant, adjuvant, or metastatic setting … (leggi tutto)